Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

(2014) Tomas Kalincik et al.   Multiple Sclerosis Journal

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

(2013) Tomas Kalincik et al.   BRAIN

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-βtherapy

(2013) M. S. Freedman   EUROPEAN JOURNAL OF NEUROLOGY

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

(2013) Tomas Kalincik et al.   PLoS One

Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data

(2012) Vanina Héraud-Bousquet et al.   BMC Medical Research Methodology

Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis

(2012) Afsaneh Shirani et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

(2011) J Theodore Phillips et al.   Multiple Sclerosis Journal

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS

(2011) Douglas S. Goodin et al.   PLoS One

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY